Aneurysmal subarachnoid hemorrhage
Conditions
Interventions
Experimental group:Edaravone Dexborneol
Sponsors
The First Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Male or female patients older than 18 years old and younger than 70 years old; 2. Patients with aneurysmal subarachnoid hemorrhage (CTA or DSA); 3. Undergo surgical treatment within 72 hours of onset (non-interventional surgery, but craniotomy microsurgical aneurysm clipping); 4. The new treatment can be applied at least once within 48 hours of onset; 5. Hunt-Hess score <= 4; 6. Improved Fisher score 1-4 points; 7. mRS score before the onset of <= 1 point; 8. The patient's hospital stay is expected to be more than 10 days; 9. The informed consent form signed by the patient or his legal representative.
Exclusion criteria
Exclusion criteria: 1. Patients who are allergic to any ingredients or excipients contained in it; 2. Patients undergoing interventional surgery; 3. Patients with subarachnoid hemorrhage caused by brain trauma, cerebral arteriovenous malformations, cerebrovascular amyloidosis and other reasons; 4. Patients with severe obstructive hydrocephalus caused by subarachnoid hemorrhage, requiring cerebrospinal fluid shunt; 5. Head CT of the admitted hospital showed that the amount of hemorrhage in the brain parenchyma>10ml; 6. Patients with a history of ischemic stroke in the past 3 months; 7. Hunt-Hess score 5 points or modified Fisher Grade 0 points; 8. Patients with unstable vital signs, deep coma, or suspected brain herniation; 9. Patients with severe heart failure; 10. Patients with severe liver and kidney failure; 11. Patients with severe respiratory failure; 12. Patients with severe coagulopathy; 13. Patients during pregnancy and lactation; 14. Patients with malignant tumors; 15. Patients with severe mental disorders or dementia; 16. Patients who are participating in other clinical research, using other research drugs or interventions; 17. Reasons why other researchers think it is not suitable to participate in this experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cerebral vasospasm; | — |
Secondary
| Measure | Time frame |
|---|---|
| mRS score; | — |
Countries
China
Contacts
Public ContactGang Chen
The First Affiliated Hospital of Soochow University
Outcome results
None listed